Medullary thyroid carcinoma: Surgical treatment advances

Expert Review of Anticancer Therapy

Volumn 7, Issue 6, 2007, Pages 877-885

  Dionigi, Gianlorenzo ^a   Bianchi, Veronica ^a   Rovera, Francesca ^a   Boni, Luigi ^a   Piantanida, Eliana ^a   Tanda, Maria Laura ^a   Dionigi, Renzo ^a   Bartalena, Luigi ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Consent; Ethics; Genetic testing; Medullary thyroid carcinoma; Mini invasive video assisted thyroidectomy; Prophylactic; RET; Thyroidectomy

Indexed keywords

AMINE; CALCITONIN; PROTEIN RET;

CANCER MORTALITY; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ENDOSCOPIC SURGERY; FAMILIAL CANCER; FEASIBILITY STUDY; GENETIC COUNSELING; GENETIC SCREENING; HISTORY OF MEDICINE; HORMONE RELEASE; HUMAN; INCIDENCE; INFORMED CONSENT; LEGAL ASPECT; MEDICAL ETHICS; MINIMALLY INVASIVE SURGERY; NEURAL CREST; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROPHYLAXIS; REVIEW; SIPPLE SYNDROME; SURGICAL TECHNIQUE; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROID SURGERY; THYROIDECTOMY; TREATMENT INDICATION;

CARCINOMA, MEDULLARY; HUMANS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 34347209765     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.6.877     Document Type: Review

References (83)

1. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(1), 313-319 (2006).
2. Casella C, Fusco M. Thyroid cancer. Epidemiol. Prev. 28(2 Suppl.), 88-91 (2004).
3. Wong KT, Ahuja AT. Ultrasound of thyroid cancer. Cancer Imaging 5, 157-166 (2005).
4. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 15(7), 708-717 (2005).
5. Rosai J. Handling of thyroid follicular patterned lesions. Endocr. Pathol. 16, 279-283 (2005).
6. LiVolsi VA. Well differentiated thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 8, 281-288 (1996).
7. Clayman GL, el-Baradie TS. Medullary thyroid cancer. Otolaryngol. Clin. N. Am. 36(1), 91-105 (2003).
8. You YN, Lakhani V, Wells SA Jr, Moley JF. Medullary thyroid cancer. Surg. Oncol. Clin. N. Am. 15(3), 639-660 (2006).
9. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin. Endocrinol. Metab. 19(1), 152-161 (1959).
10. Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79(1), 132-138 (1997).
11. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77(8), 1556-1565 (1996).
12. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83(12), 2638-2648 (1998).
13. Al-Rawi M, Wheeler MH. Medullary thyroid carcinoma - update and present management controversies. Ann. R. Coll. Surg. Engl. 88(5), 433-438 (2006).
14. Dunn JM, Farndon JR. Medullary thyroid carcinoma. Br. J. Surg. 80(1), 6-9 (1993).
15. Takami H. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocr. Pathol. 14(2), 123-131 (2003).
16. Wolfe HJ, Melvin KE, Cervi-Skinner SJ et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N. Engl. J. Med. 289(9), 437-441 (1973).
17. Machens A, Niccoli-Sire P, Hoegel J et al.; European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J Med. 349(16), 1517-1525 (2003).
18. Machens A, Holzhausen HJ, Thanh PN, Dralle H. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134(3), 425-431 (2003).
19. Beressi N, Campos JM, Beressi JP et al. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid 8(11), 1039-1044 (1998).
20. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann. Surg. 229(6), 880-887 (1999).
21. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5), 1139-1148 (2000).
22. Dolan SJ, Russell CF. Medullary thyroid carcinoma in Northern Ireland, 1967-1997. Ann. R. Coll. Surg. Engl. 82(3), 156-161 (2000).
23. Russo D, Arturi F, Chiefari E et al. A case of metastatic medullary thyroid carcinoma: early identification before surgery of an RET proto-oncogene somatic mutation in fine-needle aspirate specimens. J. Clin. Endocrinol. Metab. 82(10), 3378-3382 (1997).
24. Takano T, Miyauchi A, Matsuzuka F et al. Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy. J. Clin. Endocrinol Metab. 84(3), 951-955 (1999).
25. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J. Clin. Endocrinol. Metab. 89(1), 163-168 (2004).
26. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 10(10), 919-922 (2000).
27. Wells SA Jr, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol. Metab. Clin. N. Am. 23(1), 215-228 (1994).
28. Hyer SL, Vini L, A'Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur. J. Surg. Oncol. 26(7), 686-690 (2000).
29. Weber T, Schilling T, Frank-Raue K et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 130(6), 1044-1049 (2001).
30. Franc S, Niccoli-Sire P, Cohen R et al. French Medullary Study Group (GETC). Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 55(3), 403-409 (2001).
31. Rougier P, Parmentier C, Laplanche A et al. Medullary thyroid carcinoma: prognostic factors and treatment. Int. J. Radiat. Oncol. Biol. Phys. 9(2), 161-169 (1983).
32. Sarrazin D, Fontaine F, Rougier P et al. Role of radiotherapy in the treatment of medullary cancer of the Thyroid Bull. Cancer 71(3), 200-208 (1984).
33. Phay JE, Moley JF, Lairmore TC. Multiple endocrine neoplasias. Semin. Surg. Oncol. 18(4), 324-332 (2000).
34. Melvin KE, Tashjian AH Jr, Miller HH. Studies in familial (medullary) thyroid carcinoma. Recent Prog. Horm. Res. 28, 399-410 (1972).
35. Gagel RF, Tashjian AH Jr, Cummings T et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18-year experience. N. Engl. J. Med. 318(8), 478-484 (1988).
36. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658-5671 (2001).
37. Carney JA, Sizemore GW, Hayles AB. Multiple endocrine neoplasia, type 2B. Pathobiol. Annu. 8, 105 153 (1978).
38. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J. Pediatr. Surg. 31 (1), 177-181 (1996).
39. Sanso GE, Domene HM, Garcia R et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 94(2), 323-330 (2000).
40. Eng C. RET proto-oncogene in the development of human cancer. J. Clin. Oncol. 17(1), 380-393 (1999).
41. Frilling A, Dralle H, Eng C, Raue F, Broelsch CE. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 118(6), 1099-1103 (1995).
42. Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol. Metab. Clin. N. Am. 25(1), 1-25 (1996).
43. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr. Opin. Oncol. 19(1), 18-23 (2007).
44. Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Hoppner W. A RET double mutation in the germline of a kindred with FMTC. Exp. Clin. Endocrinol. Diabetes 108(2), 128-132 (2000).
45. Siggelkow H, Melzer A, Nolte W, Karsten K, Hoppner W, Hufner M. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. Eur. J. Endocrinol. 144(5), 467-473 (2001).
46. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J. Clin. Endocrinol. Metab. 86(3), 1104-1109 (2001).
47. Gimm O, Niederle BE, Weber T et al. RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome? Surgery 132(6), 952-959 (2002).
48. Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann. Surg. 236(5), 570-575 (2002).
49. Carlson KM, Bracamontes J, Jackson CE et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am. J. Hum. Genet. 55(6), 1076-1082 (1994).
50. Fleming JB, Lee JE, Bouvet M et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann. Surg. 230(5), 697-707 (1999).
51. Dralle H, Scheumann GF, Proye C et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J. Intern. Med. 238(4), 357-361 (1995).
52. Keatts EL, Itano J. Medullary thyroid cancer and the impact of genetic testing. Clin. J. Oncol. Nurs. 10(5), 571-575 (2006).
53. Shaha AR, Cohen T, Ghossein R, Tuttle RM. Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members. Laryngoscope 116(9), 1704-1707 (2006).
54. Tashjian AH Jr, Melvin EW. Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. N. Engl. J. Med. 279(6), 279-283 (1968).
55. Melvin KE, Tashjian AH Jr, Miller HH. Studies in familial (medullary) thyroid carcinoma. Recent Prog. Horm. Res. 28, 399-470 (1972).
56. Jackson CE, Tashjian AH Jr, Block MA. Detection of medullary thyroid cancer by calcitonin assay in families. Ann. Intern. Med. 78(6), 845-852 (1973).
57. Niccoli-Sire P, Murat A, Baudin E et al. Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumors Study Group (GETC). Eur. J. Endocrinol. 141(5), 468-474 (1999).
58. Niccoli-Sire P, Murat A, Rohmer V, French Calcitonin Tumors Group (GETC). Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. J. Clin. Endocrinol. Metab. 86(8), 3746-3753 (2001).
59. Vitale G, Ciccarelli A, Caraglia M et al. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin. Chem. 48(9), 1505-1510 (2002).
60. Cohen R, Campos JM, Salaun C. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J. Clin. Endocrinol. Metab. 85(2), 919-922 (2000).
61. Pomares FJ, Rodriguez JM, Nicolas F et al. Presurgical assessment of the tumor burden of familial medullary thyroid carcinoma by calcitonin testing. J. Am. Coll. Surg. 195(5), 630-634 (2002).
62. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'Etude des Tumeurs a Calcitonine. Clin. Endocrinol. (Oxf.) 48(3), 265-273 (1998).
63. Bachalot A, Lombardo F, Baudin E, Bidart JM, Schlumberger M. Inheritable forms of medullary thyroid carcinoma. Biochimie 84(1), 61-66 (2002).
64. Fugazzola L, Cerutti N, Mannavola D et al. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clin. Endocrinol. (Oxf.) 56(1), 53-63 (2002).
65. O'Riordain DS, O'Brien T, Weaver AL et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116(6), 1017-1023 (1994).
66. Leboulleux S, Travagli JP, Caillou B et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer 94(1), 44-50 (2002).
67. Shan L, Nakamura M, Nakamura Y et al. Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas. Jpn. J. Cancer Res. 89(9), 883-836 (1998).
68. Gagner M, Lacroix A, Prinz RA. Early experience with laparoscopic approach for adrenalectomy. Surgery 114(6), 1120-1124 (1993).
69. Duh QY. Minimally invasive endocrine surgery: standard of treatment or hype? Surgery 134(6), 849-857 (2003).
70. Gagner M. Endoscopic parathyroidectomy. Br. J. Surg. 83, 87 (1996).
71. Ohgami M, Ishii S, Ohmori T, Noga K, Furukawa T, Kitajima M. Scarless endoscopic thyroidectomy: breast approach better cosmesis. Surg. Laparosc. Endosc. Percutan. Tech. 10, 1-4 (2000).
72. Ikeda Y, Takami H, Sasaki Y, Takayama J, Niimi M, Kan S. Clinical benefits in endoscopic thyroidectomy by the axillary approach. J. Am. Coll. Surg. 196(2), 189-195 (2003).
73. Miccoli P, Berti P, Materazzi G, Minuto M, Barellini L. Minimally invasive video-assisted thyroidectomy: five years of experience. J. Am. Coll. Surg. 199(2), 243-248 (2004).
74. Miccoli P, Bellantone R, Mourad M, Walz M, Raffaelli M, Berti P. Minimally invasive video-assisted thyroidectomy: multiinstitutional experience. World J. Surg. 26(8), 972-975 (2002).
75. Berti P, Materazzi G, Picone A, Miccoli P. Limits and drawbacks of video-assisted parathyroidectomy. Br. J. Surg. 90, 743-747 (2003).
76. Spinelli C, Bertocchini A, Antonelli A, Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. J. Pediatr. Surg. 39(10), 1500-1505 (2004).
77. Miccoli P, Elisei R, Berti P et al. Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. J. Endocrinol. Invest. 27(6), 557-561 (2004).
78. Miccoli P, Elisei R, Donatini G, Materazzi G, Berti P. Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. Surg. Endosc. 21(1), 120-123 (2007).
79. Hodges FM, Svoboda JS, Van Howe RS. Prophylactic interventions on children: balancing human rights with public health. J. Med. Ethics 28(1), 10-16 (2002).
80. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 21 (12), 2397-2406 (2003).
81. Anderlik MR, Lisko EA. Medicolegal and ethical issues in genetic cancer syndromes. Semin. Surg. Oncol. 18(4), 339-346 (2000).
82. Harris M, Winship I, Spriggs M. Controversies and ethical issues in cancer-genetics clinics. Lancet Oncol. 6(5), 301-310 (2005).
83. Meyer T, Hamelmann W, Timmermann W, Meyer B, Hocht B. The advantages and disadvantages of nerve monitoring during thyroid surgery in childhood. Eur J. Pediatr. Surg. 16(6), 392-295 (2006).